Effectiveness and controversy of convalescent plasma therapy for
COVID-19 patients
Abstract
Coronavirus disease2019(COVID-19) is a pandemic with no specific
therapeutic agents and substantial mortality. It is critical to find new
treatments. Convalescent plasma, donated by persons who have recovered
from COVID-19, is the acellular component of blood that contains
antibodies, including those that specifically recognize SARS-CoV-2.
Therefore, for COVID-19 patients, Convalescent plasma, could prove
lifesaving, such as improving the clinical symptoms, increasing the
neutralizing antibody, decreasing the viral load , reducing the death
rate, with safety and without seriously ADE. Meanwhile, it is urgent to
perform large sample randomized controlled trials to confirm the
transfusion timing, dosage, frequency and actively prevent adverse
outcomes that may occur, establishing a standard procedure for treatment
from convalescent plasma collection, preservation, transport, to
transfusion.